CRANBURY, New Jersey, 2. September 2022 /PRNewswire/ — WuXi Biologics („WuXi Bio”) (2269.HK), ein weltweit führendes Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen (CRDMO), gab heute die GMP-Freigabe seiner klinischen GMP-Phase-I-Anlage für Arzneimittelwirkstoffe, MFG18,…
Related Posts
SIKA CORPORATION LAUNCHES TUFF-N-NUFF® ROCKSHIELD PRODUCT WITH NEW RAPID-EDGE SELF-FASTENING TECHNOLOGY
LYNDHURST, N.J, Aug. 18, 2022 /PRNewswire/ — Newly released Tuff-N-Nuff® with Rapid-Edge technology is a self-fastening rockshield product, designed with…
Smart Carbon Market to Attain Value of US$ 12 Bn by 2031, TMR Study
The adoption of strict regulations and an optimistic outlook for reducing carbon footprints are likely to fuel growth of the…
Talesun exhibits high-efficiency modules in the South American market
SAO PAULO, Sept. 1, 2022 /PRNewswire/ — Intersolar South America 2022, one of the largest and most influential PV trade…